

DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

February 2020

Vol. 48, No. 2

CONTENTS

ARTICLES

- Glucuronidation of Abiraterone and Its Pharmacologically Active Metabolites by UGT1A4, Influence of Polymorphic Variants and Their Potential as Inhibitors of Steroid Glucuronidation. *Joanie Vaillancourt, Véronique Turcotte, Patrick Caron, Lyne Villeneuve, Louis Lacombe, Frédéric Pouliot, Éric Lévesque, and Chantal Guillemette* **75**

- Human Cytochrome P450 1A1 Adapts Active Site for Atypical Nonplanar Substrate. *Aaron G. Bart, Ryan H. Takahashi, Xiaojing Wang, and Emily E. Scott* **86**

- Pharmacokinetics of Organic Cation Transporter 1 (OCT1) Substrates in Oct1/2 Knockout Mice and Species Difference in Hepatic OCT1-Mediated Uptake. *Bridget L. Morse, Anil Kolar, Loyd R. Hudson, Andrew T. Hogan, Lisa Hong Chen, Ryan M. Brackman, Geri A. Sawada, John K. Fallon, Philip C. Smith, and Kathleen M. Hillgren* **93**

- N-Oxygenation of Oxycodone and Retro-reduction of Oxycodone N-Oxide. *John R. Cashman, Mark Gohdes, Annelies de Kater, and Grant Schoenhard* **106**

- Mechanistic Modeling of the Hepatic Disposition of Estradiol-17 β -Glucuronide in Sandwich-Cultured Human Hepatocytes. *Katsuaki Ito, Noora Sjöstedt, and Kim L.R. Brouwer* **116**

- Piperine Is a Mechanism-Based Inactivator of CYP3A. *Tiantian Cui, Qian Wang, Xiaoxiao Tian, Kehan Zhang, Ying Peng, and Jiang Zheng* **123**

- Abundant Expression of OCT2, MATE1, OAT1, OAT3, PEPT2, BCRP, MDR1, and xCT Transporters in Blood-Arachnoid Barrier of Pig and Polarized Localizations at CSF- and Blood-Facing Plasma Membranes. *Yasuo Uchida, Ryohei Goto, Hina Takeuchi, Magdalena Łuczak, Takuya Usui, Masanori Tachikawa, and Tetsuya Terasaki* **135**

ERRATUM

- Correction to “Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in *CYP2C9* and *CYP2C19*”. **85**

Supplemental material is available online at <http://dmd.aspetjournals.org>.

About the cover: The antiandrogen abiraterone and its metabolites are glucuronidated by UGT1A4 and inhibit steroid glucuronidation. See the article by Vaillancourt et al. (dx.doi.org/10.1124/dmd.119.088229).